5F-SDB-006 is a drug that acts as a potent agonist for the cannabinoid receptors, with an EC50 of 50 nM for human CB1 receptors, and 123 nM for human CB2 receptors. It was discovered during research into the related compound APICA which had been sold illicitly as “2NE1”. 5F-SDB-006 is the terminally fluorinated analog of SDB-006, just as STS-135 is the terminally fluorinated analog of APICA
SDB-006 is an analog of the cannabimimetic indole JWH 018 adamantyl carboxamide (Item No. 9001193) in which the adamantane cage has been replaced with a phenyl ring.1 It binds the central cannabinoid (CB1) and peripheral cannabinoid (CB2) receptors with EC50 values of 19 and 134 nM, respectively.1 5-fluoro SDB-006 is an analog of SDB-006 with a fluorine atom added to the terminal carbon of the alkyl chain. While the properties of this compound are not known, this modification of similar cannabimimetic compounds typically increases affinity for both CB receptors significantly.2 This product is intended for forensic and research applications.
There have been a number of reported cases of deaths and hospitalizations in relation to this synthetic cannabinoid.It was originally developed by Pfizer in 2009 as an analgesic medication
3,4-Methylenedioxypyrovalerone (also known as MDPV, NRG-1, and imprecisely as Bath Salts, among many others) is a novel, extremely potent synthetic stimulant substance of the cathinone and pyrrolidine chemical classes that produces states of extreme stimulant euphoria, disinhibition, and sexual arousal when administered. MDPV is thought to act primarily as as a norepinephrine-dopamine reuptake inhibitor (NDRI) and possesses powerful euphoric stimulant qualities. It was first developed in the 1960s by a team at Boehringer Ingelheim.
MDPV remained an obscure stimulant until around 2004, when it was reportedly first made available to the public as a designer drug. Products labeled as “bath salts” containing MDPV were previously sold as recreational drugs in gas stations and convenience stores in the United States, similar to the marketing strategy of Spice and K2 as incense.
Historical reports show records of the preparation of MDPV for potential use as a CNS stimulant. It was claimed to have potential to be an alternative for racemic amphetamine and, although showing some desirable qualities such as reduced toxicity as compared to amphetamine, MDPV was chosen to not be developed as a medicinal drug.